Clinical Trial Update: Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study of dasatinib in combination with bendamustine for Chronic Lymphocytic Leukemia has been withdrawn. The sponsor was Bristol-Myers Squibb.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• DASATINIB (Dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: WITHDRAWN